1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,820 | 1,850 | 09.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 09.09. | HAOHAI BIOTEC (06826): (REVISED) NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 08.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 07.09. | HAOHAI BIOTEC (06826): INTERIM REPORT 2026 | 1 | HKEx | ||
| 04.09. | Dividendenbekanntmachungen (04.09.2026) | 15.537 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAON INC US0003602069 0,1 USD 0,086 EUR ACUSHNET HOLDINGS CORP US0050981085 0,255 USD 0,2193 EUR AIA GROUP LTD HK0000069689 0... ► Artikel lesen | |
| 01.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.08. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 21.08. | Shanghai Haohai Biological Technology Co., Ltd Profit Retreats In H1 | 2 | RTTNews | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 21.08. | HAOHAI BIOTEC (06826): CHANGE OF AUTHORIZED REPRESENTATIVE | - | HKEx | ||
| 21.08. | HAOHAI BIOTEC (06826): DISTRIBUTION AND PAYMENT OF 2026 INTERIM DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS | 1 | HKEx | ||
| 21.08. | HAOHAI BIOTEC (06826): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2026 | - | HKEx | ||
| 11.08. | HAOHAI BIOTEC (06826): DATE OF BOARD MEETING | 5 | HKEx | ||
| 20.07. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 22.06. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 04.06. | Dividendenbekanntmachungen (04.06.2026) | 15.641 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| 29.05. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | - | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): RESIGNATION OF AN EXECUTIVE DIRECTOR; CHANGE OF THE CHAIRMAN; AND CHANGE OF COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): POLL RESULTS OF AGM, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING; 2025 PROFIT DISTRIBUTION; CHANGE OF DIRECTORS ... | - | HKEx | ||
| 15.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,548 | +1,23 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| AMGEN | 372,00 | +2,38 % | Cantor Fitzgerald raises Amgen stock price target on portfolio strength | ||
| STRYKER | 247,70 | +0,28 % | Stryker Corporation: Stryker announces leadership succession | Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kevin Lobo to transition to Executive Chair of the Board of DirectorsCurrent President and COO Spencer Stiles appointed Chief Executive OfficerLeadership... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 668,50 | +1,43 % | Kampf gegen Hautkrebs: Wie Vidac Pharma, Biofrontera und Regeneron an verschiedenen Stellen ansetzen | Auf der Jahrestagung der Europäischen Akademie für Dermatologie und Venerologie in Wien standen zuletzt neue Ansätze für die großflächige Behandlung von Hautschäden im Fokus. Der Kampf gegen Hautkrebs... ► Artikel lesen | |
| CSL | 114,00 | +1,53 % | CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln |
CANBERA (dpa-AFX) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 316,00 | +1,28 % | BEONE MEDICINES (06160): GRANT OF RESTRICTED SHARE UNITS | ||
| CANSINO BIOLOGICS | 4,160 | 0,00 % | CanSino Biologics Inc: Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New Opportunities | HONG KONG, Aug 27, 2026 - (ACN Newswire) - CanSino Biologics Inc. ('CanSinoBIO,' 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately... ► Artikel lesen | |
| SINO BIOPHARM | 0,616 | -1,93 % | SBP GROUP: TQC3721 Inhalation Suspension PDE3/4 Inhibitor Phase III Clinical Trial Completes Patient Enrollment | ||
| BIOMERIEUX | 83,20 | +3,55 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| ZAI LAB LTD ADR | 21,800 | -1,80 % | Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential | ||
| CSTONE PHARMACEUTICALS | 0,562 | -3,07 % | CStone Pharmaceuticals: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum | CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy... ► Artikel lesen | |
| CASI PHARMACEUTICALS | 0,214 | -4,13 % | CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results | SOUTH SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2026 / CASI Pharmaceuticals, Inc. (OTCQB:CASIF), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody... ► Artikel lesen | |
| 3SBIO | 1,777 | +3,39 % | 3SBIO Repurchases 1.7 million Shares Yesterday for HKD26.5 million | ||
| INNOVENT BIOLOGICS | 10,684 | +1,42 % | Innovent Biologics: Innovent Announces Phase 3 RESTORE-3 Study of SYCUME (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease | SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | -1,40 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript |
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,790 Euro und damit +0,56 % im Plus. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.